AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04297553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-Fresh
Description: Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Receiving hCG 5000IU x 2 (10000IU) after Oocytes retrieval. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Fresh embryos transfer will be performed on day 3 using HRT protocol with a maximum of 2 embryos transferred.
Study NCT04297553 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAPA-Freeze-only
Description: Receiving FSH (Menopur, Ferring) for 2 days on day 2/3 of the menstrual cycle (spontaneous/ OCP administration) and an ultrasound scan will be performed subsequently. Oocytes retrieval will be performed 42 hours after the last injection. Pre-maturation will last for 24-30 hours. ICSI will be used for insemination. Freeze-only on day 3 and frozen embryo transfer will be performed on the subsequent cycle using HRT protocol with a maximum of 2 embryos transferred.
Study NCT02623426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant 0.7 mg
Description: Standard preparation as described for intravitreal injections.
Study NCT02623426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Methotrexate 400 µg
Description: Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Study NCT02623426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Ranibizumab 0.5 mg
Description: Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Study NCT04337515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMacs®
Description: CliniMACS® CD34 Reagent System is now indicated for processing hematopoietic progenitor cells collected by apheresis (PBSC) from an allogeneic, HLA-identical MSD to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional GVHD prophylaxis in patients with AML in first morphologic complete remission (CR1).
Study NCT01995006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metamizole
Description: metamizol tablets (500mg): 1000mg TID during 7 days
Study NCT01995006 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets (500mg): 500 mg BID during 7 days
Study NCT02700074 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Intervention is not a part of this study.
Study NCT02535247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MK-3475
Study NCT02535247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Study NCT02535247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Copanlisib
Study NCT05021588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: steroid and anticoagulants according to different protocols.
Description: As no standard treatment for COVID-19 was approved; there are many treatment protocols for anti-inflammatory corticosteroids and anti-coagulantsfor severe COVID-19 pneumonia cases, this study aims to assess the most suitable modality in this high-risk group.
Study NCT01576627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc citrate
Description: 10 mg of zinc as either zinc citrate
Study NCT03874000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO
Study NCT01383070 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactational Counseling by Cell phone
Description: The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
Study NCT01383070 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Lactational Counseling by Cell phone
Description: The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
Study NCT02160873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chocolate milk
Description: 12 oz, 7-8 hours prior to exercise trial (night before)
Study NCT02160873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: flavor-matched placebo
Description: 12 oz, non-caloric flavor-matched placebo
Study NCT01965067 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Description: sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state
Study NCT01965067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state~Reversal effect of sugammadex in temperature state
Study NCT01509859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFNA proximal femur nail device (Synthes)
Description: synthes PFNA proximal femur nail device
Study NCT01509859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INTERTAN proximal femur nail device (Smith&Nephew)
Description: Smith\&Nephew INTERTAN proximal femur nail device
Study NCT00686400 — intervention group
Intervention type: OTHER
Intervention: TAU = treatment as usual
Description: medication and psychosocial interventions to be chosen by treating psychiatrist
Study NCT01575340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fish oil encapsuled
Description: 2 g/d (4 capsules of 500 mg)for 9 weeks
Study NCT02393313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
Study NCT02393313 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rayner T-flex Toric IOLs
Study NCT00977262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of saturated fat
Study NCT00977262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High monounsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage of monounsaturated fat
Study NCT01576627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Gluconate
Description: 10 mg of zinc as either zinc gluconate
Study NCT01576627 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc oxide
Description: 10 mg of zinc as either zinc oxide
Study NCT03012620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Treatment
Study NCT02018042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.~The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug.
Study NCT04507789 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Exercise protocol will consist of the recommended special exercise sets for upper extremity problems on mastectomy patients. The upper extremity protocol has published in 2018 by Richmond and friends called prevention of musculoskeletal shoulder problems after breast cancer treatment UK-PROSPER protocol.this special protocol has unique exercise sets for to restore shoulder range of motion, to maintain good force level of upper extremity muscles and stretch exercises especially to the muscles around the radiotherapy area. Exercises will be done under the supervision of a specialized physiotherapist about upper extremity disorders.
Study NCT04507789 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine radiotherapy protokol
Description: This intervention is only an observation to patients during their routine radiotherapy protocol. There will be no exercise intervention for the upper extremity for the patient in this group.
Study NCT03515837 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV infusion
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: vigorous exercise intervention - cybercycling
Description: perform HIIT exercise on cybercycles aided by electronic racing and other games
Study NCT02179762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Logs
Description: The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: IV infusion
Study NCT03515837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline solution
Description: IV infusion
Study NCT00810615 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen @ 2.4 ATA
Description: Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
Study NCT00810615 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Study NCT03967106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ischaemic Preconditioning
Description: IPC to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg above the systolic blood pressure (BP) followed by 5 minute cuff deflation.
Study NCT00977262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat shake
Description: milkshake containing 95 gram of fat, high percentage polyunsaturated fat
Study NCT03357601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: The participant will perform HIIT where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 20 seconds of high intensity interval exercise at an all out intensity separated by 2 minutes of active recovery at 30% MHR. The interval will be repeated six times. Once completing all six intervals, participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
Study NCT03357601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCEET
Description: The participant will perform MCEET, where they will warm up for 3 minutes at 30% maximum heart rate (MHR), followed by 14 minutes of moderate, continuous endurance exercise at 70% MHR. Participants will cool down for 3 minutes. This training program will be performed three times per week for five weeks.
Study NCT03967106 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham intervention to the upper arm using a manual blood pressure machine with cuff. Three cycles of 5 minute cuff inflation to 30mmHg below the diastolic blood pressure (BP) followed by 5 minute cuff deflation.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos
Description: MCP-L consists of seven-60 minute-individual sessions. The seven sessions are expected to be delivered every week or every two weeks over a span of 7-14 weeks.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Cancer Therapy - Spiritual Well-Being Scale
Description: Determines the degree of spiritual well-being
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Psychotherapy for Latinos for Waitlist Control Patients
Description: Waitlist Control Patients in the control condition will be allocated to a waitlist group to receive the intervention approximately three months after randomization.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study NCT04537936 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-assessment questionnaire
Description: Which includes 10 standardized scales Assessment/Evaluation Plan, Phase 1, 4 - Quantitative Measure Questionnaire).The interview guide will inquire about the comprehension and acceptability of, and alternative options for, these intervention components.
Study NCT00996632 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
Description: mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
Study NCT00996632 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional diarthermy knife
Description: mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
Study NCT02396069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JPI-289
Description: PARP-1 inhibitor
Study NCT02607579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Study NCT02396069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00142844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Study NCT02607579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Study NCT03806738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention-specific Carevive questionnaire
Description: includes standard of care questions with additional decision-making questions
Study NCT03806738 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care questionnaire
Description: includes the standard of care questions that are already in place for Carevive questionnaires
Study NCT03540927 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PM+ for entrepreneurs
Description: The intervention arm will receive 5 weekly face-to-face group sessions of Problem Management Plus(PM+ for entrepreneurs). Duration of each session is 2 hours. Session 1 orients participants to the intervention with motivational interviewing techniques to improve engagement,provides information about common reactions to adversity, and trains participants in a basic stress management strategy (slow breathing). Session 2 addresses a participant-selected problem using problem-solving techniques. Sessions 3 and 4 support participants' continued application of problem solving, behavioral activation, and stress management and introduce strategies to strengthen social support networks. In session 5, education about retaining intervention gains and self-care are provided and all learned strategies are reviewed.
Study NCT03540927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash transfer to the Entrepreneurs
Description: The entrepreneurs in the control arm will receive cash transfer only for their businesses.
Study NCT03540927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash transfer to the Entrepreneurs
Description: The entrepreneurs in the control arm will receive cash transfer only for their businesses.
Study NCT03655158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ozone device ( Ozonytron XL )
Description: The adjustment of the ozone generator was %75 power for 30 seconds (75 ug/ml) based on manufacturer's instructions
Study NCT00142844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Study NCT00142844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01185730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right Heart Catheterization
Description: all patients of the all centers will have Right Heart Catheterization at the diagnosis
Study NCT00203957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
Study NCT02079428 — intervention group
Intervention type: OTHER
Intervention: No interventions
Study NCT03959137 — intervention group
Intervention type: OTHER
Intervention: None - Common practice
Description: None - Common practice
Study NCT04737811 — intervention group
Intervention type: OTHER
Intervention: Turkish Version of Swallowing Disturbance Questionnaire
Description: The Turkish Version of Swallowing Disturbance Questionnaire consists of 15 questions related with dysphagia.
Study NCT06110221 — intervention group
Intervention type: OTHER
Intervention: Periodontal clinical measurements, GCF and saliva sampling
Description: Clinical periodontal indices included probing depth (PD), clinical attachment loss (CAL), the dichotomous scoring of bleeding on probing (BOP +/-), gingival index (GI), and plaque index (PI). Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF and saliva samples were obtained 1 day following the clinical measurements. Unstimulated whole saliva was collected from all participants. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.
Study NCT00196573 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder bursectomy alone
Study NCT02711579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02711579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02231307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC FIX Birch
Study NCT02231307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBLIVAC FIX Birch
Study NCT00991042 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood collect
Description: Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
Study NCT02956005 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ENVARSUS®
Description: ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
Study NCT00561184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
Study NCT00561184 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 influenza vaccine
Description: One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen